BioWorld always honors news embargoes. An early heads up gives us extra time to prepare and conduct research. We promise to keep your news confidential until the stated embargo lifts. BioWorld is the ...

Actionable intelligence on advances in medical devices and technologies for 20+ years ...

BioWorld Premium offers comprehensive market insights with access to BioWorld, BioWorld MedTech, and BioWorld Asia in one convenient subscription.

Humanwell Healthcare (Group) Co. Ltd. has described fused ring compounds acting as angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of disorders of the ovary and ...

The European Commission approved up to €403 million ($472 million) in funding to support development of innovations in medical devices in the region. The funds will go towards 10 companies that ...

Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, ...

China’s CAR T market is expected to grow from $72 million in 2022 to $342 million over the next decade. There are currently more than 400 CAR T therapies in the pipeline in China, and most of these ...

The Trump administration released an action plan for AI, which includes an exports program for full-stack AI in areas such as health care. The announcement drew the support of the Advanced Medical ...

The 2025 edition of Clarivate’s Drugs to Watch features 11 candidates or approved therapeutics that may well revolutionize treatments or become blockbusters. The 12th annual report has a strong track ...

New guidance by the Medical Device Coordination Group spells out many of the routine aspects of compliance with the In Vitro Diagnostic Regulation, but test developers should remain aware of the ...

Recursion Pharmaceuticals Inc. has gained IND clearance from the FDA for a phase I/II trial of REC-1245 in a biomarker-enriched patient population, including patients with solid tumors and lymphoma.

Kymera Therapeutics Inc. has unveiled two new first-in-class oral degrader programs for immune-mediated diseases: KT-621, a STAT6 degrader, and KT-294, a TYK2 degrader.